Clinical Trial Update: Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

Amgen's Phase 2 study evaluating tezepelumab in adults with chronic spontaneous urticaria has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: Amgen | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2024-05-01